Provider Services

Maturity-Onset Diabetes of the Young

Diabetes: Is It Type 1, Type 2, or something else?

The Centers for Disease Control and Prevention (CDC) estimates that more than 30 million Americans suffer from diabetes.¹ Maturity-Onset Diabetes of the Young (MODY) is a form of monogenic diabetes—diabetes that results from a change or mutation in a single gene.² While MODY only makes up about 1% of diabetes cases in the US, up to 95% of cases are misdiagnosed as Type 1 or Type 2 diabetes.² Accurate diagnosis enables appropriate treatment.^2-3

Optimizing Inflammatory Bowel Disease Treatment through Biologic Drug Monitoring

LabCorp's ​DoseASSURE test portfolio provides tests for both drug concentration (TDM) and anti-drug antibody (immunogenicity)

Prediabetes: Know Your Patients’ Risks

There are an estimated 84 million adults 18 years and older in the U.S. who are prediabetic or at risk for developing diabetes.¹  Prediabetes is characterized as higher than normal glucose levels but not high enough to meet criteria for diabetes.²  It is associated with –

Empower Change | Address the Opioid Crisis

Empower Change | Address the Opioid Crisis

LabCorp is the exclusive national laboratory integrated within The Recovery Platform^♦, allowing for seamless access to LabCorp’s medication-assisted treatment (MAT) monitoring services.  The combination of LabCorp’s testing and The Recovery Platform’s software supports compliance with medication-assisted treatment, and helps patients stay on track with their recovery.